Stockscreener 앱 받기
0.303
10.64%
0.0229
전일 마감가:
$0.2801
열려 있는:
$0.2821
하루 거래량:
976.61K
Relative Volume:
1.58
시가총액:
$3.12M
수익:
$200.00K
순이익/손실:
$-10.95M
주가수익비율:
-0.1535
EPS:
-1.9738
순현금흐름:
$-10.78M
1주 성능:
-2.58%
1개월 성능:
-72.33%
6개월 성능:
-77.21%
1년 성능:
-84.15%
1일 변동 폭
$0.2821
$0.3199
1주일 범위
$0.28
$0.339
52주 변동 폭
$0.28
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
명칭
Soligenix Inc
전화
609-538-8200
주소
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.303 | 2.89M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
452.14 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
716.50 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.59 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
313.87 | 32.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-28 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2018-01-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 재확인 | Maxim Group | Buy |
| 2017-07-17 | 개시 | H.C. Wainwright | Buy |
Soligenix Inc 주식(SNGX)의 최신 뉴스
TradingKey - TradingKey
Soligenix (SNGX) registers 1,054,688 resale shares; Q1 cash $6.03M - Stock Titan
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
HyBryte CTCL trial halted as Soligenix (SNGX) faces going concern risk - Stock Titan
Soligenix (SNGX) Faces Setback in FLASH2 Study Results - GuruFocus
Soligenix Releases Q1 2026 Financial Results - AlphaStreet
Soligenix 1Q Loss/Shr 28c >SNGX - Moomoo
Soligenix Announces Recent Updates And First Quarter 2026 Financial Results - TradingView
Soligenix Anticipates HyBryte™ Phase 3 Results in Second Half of 2026, Reports $28.3 Million in Cash - geneonline.com
Soligenix Q1 net loss narrows on lower expenses - TradingView
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - ChartMill
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment - MSN
A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX phase 3 trial halted on HyBryte - MSN
SNGX: FLASH2 Trial Recommended to Stop for Futility - Yahoo Finance
Soligenix signals pivotal year with new drug progress - Community News
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives - TipRanks
SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment - Stocktwits
SNGX Phase 3 Trial Halted on HyBryte - Yahoo Finance
Soligenix halts lymphoma drug trial after futility analysis - Investing.com UK
Disappointment in Interim Results for Soligenix (SNGX) in Phase 3 Trial - GuruFocus
Why Is Soligenix Stock Sinking Tuesday? - Benzinga
SNGX - Finviz
Soligenix halts lymphoma drug trial after futility analysis By Investing.com - Investing.com Australia
HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk - Stock Titan
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma – Company AnnouncementFT.com - Financial Times
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease (PR Newswire) - Aktiellt
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency (PR Newswire) - Aktiellt
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - TipRanks
Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - NewMediaWire
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - TipRanks
Soligenix (SNGX) price target decreased by 14.29% to 15.30 - MSN
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results - The Globe and Mail
Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results - NewMediaWire
Soligenix secures EU orphan drug designation for Behçet’s disease therapy - MSN
Soligenix (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development - The Globe and Mail
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Soligenix Inc (SNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.26%
4.20%
자본화:
|
볼륨(24시간):